Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Cyclone Narelle turns Australian skies blood red in ‘apocalyptic’ scenes - 2Watch SpaceX launch NASA's Pandora exoplanet-studying satellite on Jan. 11
- 3Palestinians protest against Israel's new death penalty law
- 4Doggie diversity in size and shape began at least 11,000 years ago
- 5Flourishing in Retirement: Individual Accounts of Post-Vocation Satisfaction
- 13 must-see moon events in 2026: Eclipses, supermoons, conjunctions and more
- Germany's far-right AfD tops poll ahead of Merz's conservatives
- Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue
- 6 U.S. States for Climbing
- Robyn returns to music with 'Dopamine,' her 1st single in 7 years: 'Came to save music once again'
- Presenting Nintendo's New Pastel Satisfaction Con Tones for Switch Gamers: 3 Upscale Choices
- Remain Fit: Powerful Wellness and Work-out Schedules for a Better You
- 5 Most Expected Film Delivery
- Artemis 2 astronauts are about to see one of the rarest skywatching sights of all — a solar eclipse from beyond the moon
